Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 79 articles:
HTML format



Single Articles


    January 2022
  1. MOROZUMI K, Mitsuzuka K, Narita S, Takahashi M, et al
    Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score >/=8.
    Int J Urol. 2022 Jan 18. doi: 10.1111/iju.14781.
    PubMed     Abstract available


  2. HASEGAWA M, Yamada K, Shigeta K, Yuzuriha S, et al
    How long should urologists observe patients with prostate cancer after radical prostatectomy? Weibull analysis.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14774.
    PubMed     Abstract available


  3. YAMASHITA S, Kawabata H, Deguchi R, Ueda Y, et al
    Myosteatosis as a novel predictor of urinary incontinence after robot-assisted radical prostatectomy.
    Int J Urol. 2022;29:34-40.
    PubMed     Abstract available


    December 2021
  4. TAKAHARA K, Naiki T, Ito T, Nakane K, et al
    Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
    Int J Urol. 2021 Dec 4. doi: 10.1111/iju.14754.
    PubMed     Abstract available


    November 2021
  5. WURNSCHIMMEL C, Wenzel M, Chierigo F, Simone Flammia R, et al
    Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 17. doi: 10.1111/iju.14743.
    PubMed    


  6. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.
    Int J Urol. 2021 Nov 11. doi: 10.1111/iju.14738.
    PubMed     Abstract available


  7. SO WZ, Wang Z, Tiong HY
    Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 5. doi: 10.1111/iju.14741.
    PubMed    


    October 2021
  8. YUASA T
    Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Oct 6. doi: 10.1111/iju.14725.
    PubMed    


  9. AKAKURA K
    Editorial Comment to External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Oct 4. doi: 10.1111/iju.14723.
    PubMed    


  10. YAMAMOTO S
    Editorial Comment to Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1045-1046.
    PubMed    


  11. FUKUNAGA A, Maejima A, Shinoda Y, Matsui Y, et al
    Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1039-1045.
    PubMed     Abstract available


  12. TEO XL, Lim SK
    Targeting the vessels first: A modified surgical technique for prostatic paraganglioma.
    Int J Urol. 2021;28:1073-1074.
    PubMed    


    September 2021
  13. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14701.
    PubMed     Abstract available


  14. SHIOTA M, Blas L, Kobayashi S, Matsumoto T, et al
    Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14702.
    PubMed     Abstract available


  15. KADONO Y
    Editorial Comment to Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14690.
    PubMed    


  16. COLARIETI A, Thiruchelvam N, Barrett T
    Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: A literature review.
    Int J Urol. 2021;28:890-897.
    PubMed     Abstract available


    August 2021
  17. MAESAKA F, Tanaka N, Nakai Y, Asakawa I, et al
    Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Aug 10. doi: 10.1111/iju.14667.
    PubMed     Abstract available


  18. NAKAI Y, Tanaka N, Fujii T, Miyake M, et al
    Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
    Int J Urol. 2021 Aug 5. doi: 10.1111/iju.14666.
    PubMed     Abstract available


    July 2021
  19. MIYAMOTO S, Goto K, Honda Y, Terada H, et al
    Tumor contact length of prostate cancer determined by a three-dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence.
    Int J Urol. 2021 Jul 5. doi: 10.1111/iju.14633.
    PubMed     Abstract available


  20. SHIGEMURA K, Fujisawa M
    Prevention and management of infectious complications in prostate biopsy: A review.
    Int J Urol. 2021;28:714-719.
    PubMed     Abstract available


    June 2021
  21. SUGIHARA T
    Editorial Comment to Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 Jun 24. doi: 10.1111/iju.14620.
    PubMed    


  22. NAKAJIMA K, Mizokami A, Matsuyama H, Ichikawa T, et al
    Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
    Int J Urol. 2021 Jun 19. doi: 10.1111/iju.14614.
    PubMed     Abstract available


  23. ANDELA CD, Matte R, Jazet IM, Zonneveld WC, et al
    Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.
    Int J Urol. 2021 Jun 14. doi: 10.1111/iju.14596.
    PubMed     Abstract available


  24. KIMURA Y, Honda M, Teraoka S, Yumioka T, et al
    Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis.
    Int J Urol. 2021;28:637-642.
    PubMed     Abstract available


  25. TAGUCHI S, Morikawa T, Shibahara J, Fukuhara H, et al
    Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review.
    Int J Urol. 2021;28:614-621.
    PubMed     Abstract available


    May 2021
  26. STOLZENBACH LF, Deuker M, Colla-Ruvolo C, Nocera L, et al
    Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
    Int J Urol. 2021 May 28. doi: 10.1111/iju.14586.
    PubMed     Abstract available


  27. CHIKAMATSU S, Shiota M, Onozawa M, Hinotsu S, et al
    Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
    Int J Urol. 2021 May 24. doi: 10.1111/iju.14605.
    PubMed     Abstract available


  28. INOUE T, Yoshimura K, Terada N, Tsukino H, et al
    Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
    Int J Urol. 2021 May 18. doi: 10.1111/iju.14590.
    PubMed     Abstract available


  29. WURNSCHIMMEL C, Wenzel M, Colla Ruvolo C, Nocera L, et al
    Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 May 15. doi: 10.1111/iju.14595.
    PubMed     Abstract available


  30. IGUCHI T, Kimura G, Fukasawa S, Suzuki H, et al
    Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Int J Urol. 2021 May 6. doi: 10.1111/iju.14568.
    PubMed     Abstract available


  31. CLAPS F, Ramirez-Backhaus M, Mir Maresma MC, Gomez-Ferrer A, et al
    Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:566-572.
    PubMed     Abstract available


  32. MATTI B, Zargar-Shoshtari K
    Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.
    Int J Urol. 2021;28:578-583.
    PubMed     Abstract available


  33. LOW AW, Chen K, Tan YG, Ng TK, et al
    Ambulatory robot-assisted laparoscopic radical prostatectomy with extended recovery by total extraperitoneal approach.
    Int J Urol. 2021;28:561-565.
    PubMed     Abstract available


    April 2021
  34. YOSHIDA S, Fujii Y
    Editorial Comment to Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14578.
    PubMed    


  35. AIZAWA R, Takayama K, Nakamura K, Ogata T, et al
    Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 2. doi: 10.1111/iju.14567.
    PubMed     Abstract available


  36. TATENUMA T, Makiyama K, Ito Y, Muraoka K, et al
    Correlation of urinary loss rate after catheter removal and long-term urinary continence after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:440-443.
    PubMed     Abstract available


  37. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Comprehensive approach for preserving cavernous nerves and erectile function after radical prostatectomy in the era of robotic surgery.
    Int J Urol. 2021;28:360-368.
    PubMed     Abstract available


    March 2021
  38. YOSHIDA S, Takahara T, Arita Y, Sakaino S, et al
    Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond.
    Int J Urol. 2021 Mar 6. doi: 10.1111/iju.14497.
    PubMed     Abstract available


  39. HATAKEYAMA S, Ohyama C
    Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Mar 4. doi: 10.1111/iju.14539.
    PubMed    


    February 2021
  40. SHIOTA M, Sumikawa R, Onozawa M, Hinotsu S, et al
    Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Feb 24. doi: 10.1111/iju.14518.
    PubMed     Abstract available


  41. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Editorial Comment to Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
    Int J Urol. 2021 Feb 7. doi: 10.1111/iju.14511.
    PubMed    


  42. MINAGAWA T, Oguchi T, Saitou T, Fukazawa A, et al
    Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
    Int J Urol. 2021 Feb 7. doi: 10.1111/iju.14487.
    PubMed     Abstract available


  43. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed     Abstract available


    January 2021
  44. HASHIMOTO T
    Editorial Comment to Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy.
    Int J Urol. 2021 Jan 28. doi: 10.1111/iju.14514.
    PubMed    


  45. NAGATA M
    Editorial Comment from Dr Nagata to Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2021 Jan 16. doi: 10.1111/iju.14494.
    PubMed    


  46. MILONAS D, Muilwijk T, Venclovas Z, Devos G, et al
    Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy.
    Int J Urol. 2021 Jan 6. doi: 10.1111/iju.14471.
    PubMed     Abstract available


  47. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed     Abstract available


    December 2020
  48. URABE F
    Editorial Comment from Dr Urabe to Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2020 Dec 19. doi: 10.1111/iju.14467.
    PubMed    


  49. JIA W, Wu B, Shao Y, Cao X, et al
    Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2020 Dec 18. doi: 10.1111/iju.14464.
    PubMed     Abstract available


  50. SAKAMOTO S
    Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Int J Urol. 2020 Dec 16. doi: 10.1111/iju.14470.
    PubMed    


  51. UEMURA H, Arai G, Uemura H, Suzuki H, et al
    Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Int J Urol. 2020 Dec 8. doi: 10.1111/iju.14447.
    PubMed     Abstract available


    November 2020
  52. KATO M, Sasaki T, Inoue T
    Current experimental human tissue-derived models for prostate cancer research.
    Int J Urol. 2020 Nov 27. doi: 10.1111/iju.14441.
    PubMed     Abstract available


  53. SHIRAISHI K
    Editorial Comment to Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Nov 24. doi: 10.1111/iju.14446.
    PubMed    


  54. YOSHIDA S, Takahara T, Yokoyama M, Matsuoka Y, et al
    Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer?
    Int J Urol. 2020 Nov 2. doi: 10.1111/iju.14421.
    PubMed    


  55. MORITA M
    Editorial Comment to Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study.
    Int J Urol. 2020;27:1017-1018.
    PubMed    


    October 2020
  56. SUGIURA M, Sato H, Kanesaka M, Imamura Y, et al
    Epigenetic modifications in prostate cancer.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14406.
    PubMed     Abstract available


  57. MATSUOKA Y, Uehara S, Yoshida S, Tanaka H, et al
    Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14410.
    PubMed    


  58. NISHIMOTO M, Fujita K, Minami T, Yoshimura K, et al
    Editorial Comment to Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Oct 17. doi: 10.1111/iju.14386.
    PubMed    


  59. HATAKEYAMA S, Ohyama C
    Response to Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Oct 12. doi: 10.1111/iju.14399.
    PubMed    


  60. IWAMURA H, Hatakeyama S, Narita S, Arai Y, et al
    Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study.
    Int J Urol. 2020 Oct 8. doi: 10.1111/iju.14392.
    PubMed    


  61. TAY KJ
    Editorial Comment from Dr Tay to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020;27:891-892.
    PubMed    


    September 2020
  62. SHIOTA M, Machidori A, Abe T, Monji K, et al
    Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
    Int J Urol. 2020 Sep 15. doi: 10.1111/iju.14366.
    PubMed     Abstract available


  63. SUGIMURA R, Kawahara T, Uemura H
    Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Sep 13. doi: 10.1111/iju.14371.
    PubMed    


  64. SHIGETA K, Kikuchi E, Matsushima M, Ogihara K, et al
    Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Sep 6. doi: 10.1111/iju.14358.
    PubMed     Abstract available


    August 2020
  65. KANEKO M, Yip W, Abreu AL
    Editorial Comment from Dr Kaneko et al. to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14362.
    PubMed    


  66. SHOJI S
    Editorial Comment from Dr Shoji to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14353.
    PubMed    


  67. KAWAHARA T
    Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Aug 8. doi: 10.1111/iju.14346.
    PubMed    


  68. AYDIN AM, Gage K, Dhillon J, Cheriyan SK, et al
    Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 6. doi: 10.1111/iju.14321.
    PubMed     Abstract available


    July 2020
  69. IPPOLITO D, Querques G, Pecorelli A, Perugini G, et al
    Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model.
    Int J Urol. 2020 Jul 25. doi: 10.1111/iju.14316.
    PubMed     Abstract available


  70. MARTELL K
    Editorial Comment to High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 22. doi: 10.1111/iju.14328.
    PubMed    


  71. VAN POPPEL H, Abrahamsson PA
    Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Jul 13. doi: 10.1111/iju.14303.
    PubMed     Abstract available


  72. KASAHARA T, Ishizaki F, Kazama A, Yuki E, et al
    High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 7. doi: 10.1111/iju.14305.
    PubMed     Abstract available


  73. HAGHSHENO MA, Hammarsten J, Peeker R, Behre CJ, et al
    Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer.
    Int J Urol. 2020 Jul 6. doi: 10.1111/iju.14304.
    PubMed    


    June 2020
  74. NAKAI Y, Tanaka N, Asakawa I, Anai S, et al
    Biochemical control of the combination of cyclooxygenase-2 inhibitor and (125) I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14294.
    PubMed     Abstract available


  75. MOMOTA M, Hatakeyama S, Soma O, Tanaka T, et al
    Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14256.
    PubMed     Abstract available


    May 2020
  76. KATO M
    Editorial Comment to Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 30. doi: 10.1111/iju.14278.
    PubMed    


  77. HATAKEYAMA S, Narita S, Takahashi M, Sakurai T, et al
    Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 16. doi: 10.1111/iju.14258.
    PubMed     Abstract available


    April 2020
  78. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer.
    Int J Urol. 2020 Apr 14. doi: 10.1111/iju.14249.
    PubMed    


    March 2020
  79. KAWAHARA T, Miyoshi Y, Uemura H
    Re: Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2020 Mar 31. doi: 10.1111/iju.14237.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: